WINTON GROUP Ltd purchased a new stake in Bruker Co. (NASDAQ:BRKR - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,584 shares of the medical research company's stock, valued at approximately $562,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BRKR. Cerity Partners LLC increased its holdings in shares of Bruker by 446.8% during the 3rd quarter. Cerity Partners LLC now owns 27,998 shares of the medical research company's stock valued at $1,934,000 after purchasing an additional 22,878 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in Bruker during the third quarter valued at $435,000. Bank of Montreal Can increased its holdings in Bruker by 31.2% in the third quarter. Bank of Montreal Can now owns 61,138 shares of the medical research company's stock valued at $4,321,000 after buying an additional 14,547 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Bruker by 3.8% in the third quarter. The Manufacturers Life Insurance Company now owns 115,616 shares of the medical research company's stock worth $7,984,000 after acquiring an additional 4,247 shares during the period. Finally, Glenmede Trust Co. NA boosted its stake in shares of Bruker by 41.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 5,772 shares of the medical research company's stock worth $399,000 after acquiring an additional 1,680 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research firms recently weighed in on BRKR. The Goldman Sachs Group raised Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target for the company in a report on Thursday, December 5th. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Barclays decreased their target price on Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a research report on Monday, February 10th. Stifel Nicolaus cut their price target on shares of Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Finally, Bank of America increased their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a report on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, Bruker has an average rating of "Moderate Buy" and an average price target of $70.50.
View Our Latest Analysis on BRKR
Bruker Price Performance
Shares of Bruker stock traded down $1.20 during trading hours on Friday, reaching $36.46. 4,101,408 shares of the company's stock were exchanged, compared to its average volume of 1,398,669. The business has a fifty day moving average of $48.64 and a two-hundred day moving average of $56.13. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $5.53 billion, a P/E ratio of 47.97, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker Co. has a 1 year low of $34.13 and a 1 year high of $91.47.
Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, research analysts predict that Bruker Co. will post 2.69 earnings per share for the current fiscal year.
Bruker Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were given a dividend of $0.05 per share. The ex-dividend date was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.55%. Bruker's payout ratio is 26.32%.
Bruker Company Profile
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Articles
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
